Vivek Ramaswamy is an American politician and entrepreneur who has walked an impressive journey from academia to becoming one of the most successful entrepreneurs and a presidential candidate. The American millionaire investor is known for his ventures in the pharmaceutical and asset management industries. As of 2025, Vivek Ramaswamy's net...
One of the pharma stocks got a price target boost after a successful study. Teva Pharmaceutical (NYSE:TEVA) and Sanofi (NASDAQ:SNY) stocks were rising on Tuesday after the companies announced successful results of a phase 2 study involving the treatment of patients with ulcerative colitis (UC) and Crohn’s disease (CD). The study...
NEW YORK, NY, THURSDAY, AUGUST 31, 2023 - Today, investors released a statement voicing deep concern about lawsuits brought by pharma companies and trade groups to block the U.S. government’s ability to negotiate fair drug prices for Medicare beneficiaries. The investors are predominantly faith-based members of the Interfaith Center on...
Despite the continued inflationary pressures, the second quarter (Q2) of 2023 yielded promising outcomes for the top 20 global biopharmaceutical companies. The aggregate market capitalization demonstrated a resilient upswing of 2.3%, surging from $3.49 trillion during the first quarter (Q1) of 2023 to an impressive $3.56 trillion in Q2 2023,...
The latest report from Dan Lefkovitz, strategist at Morningstar Indexes, examines dividend-stock underperformance in 2023. Recent weakness among Morningstar dividend indexes is less about interest rates than a narrow equity market; long-term upside remains. Equities have logged solid gains so far this year. After the aggressive monetary policy response to...
The biopharmaceutical industry had an exceptional year in 2022 with notable success for those with COVID-19 vaccines. The majority (15) of the top 20 publicly traded global innovative biopharma companies reported a 5.2% growth in the aggregate revenue to $868.97 billion from 2021 to 2022, reveals GlobalData, a leading data...
Morningstar recently launched the Morningstar Global Brain Health Innovation Index and has published a new research paper that outlines the Index and the next wave of innovation in neurology, with expected progress in treatment options for disorders such as Alzheimer’s, Parkinson’s, dementia, and more. The oncoming wave of innovation has...
After a Q4 beat garnered little immediate reaction, OCUP stock has now traded more than 40% higher Clinical-stage ophthalmic biopharmaceutical company Ocuphire Pharma, Inc. (NASDAQ:OCUP) announced its fourth-quarter and year-end financial results on March 30, indicating a successful year with significant clinical, regulatory, patent, and strategic partner milestones. Q1 2023 hedge...
Sorrento Therapeutics is on the move following preliminary results from Scilex. Scilex is Sorrento Therapeutics' publicly traded subsidiary. The company's 1st product to market is making money. 5 stocks we like better than Sorrento Therapeutics A pair of hot pharma stocks are on the move and could become the next...
Madrigal Pharmaceuticals released the results of the long-awaited NASH trial. The results are positive and may lead to accelerated approval. Short-interest remains high and is helping to drive the action. 5 stocks we like better than Madrigal Pharmaceuticals If you want to know why Madrigal Pharmaceuticals (NASDAQ:MDGL) is up 200%...
Bargain hunters swooped in on Catalent stock after it entered oversold territory. Catalent’s end-market demand appears to be deteriorating. The disappointing start to the year led management to backpedal on its outlook. The company still has valuable partnerships with leading drug makers and consumer health companies. Last fall, Catalent, Inc....
Small-cap biotech Catalyst Pharmaceuticals recently joined the S&P 600 index, which means institutions must own shares to track the index The company has a steady history of price appreciation going back one year, even while the broad market declined Catalyst has been outpacing the S&P 600 index by a wide...
Investors are bracing for billions of dollars in losses due to lawsuits filed over the heartburn drug Zantac. The three U.K.-based drugmakers shed tens of billions of dollars from their market caps amid the potential for litigation in the U.S. Although the issues and resulting lawsuits associated with Zantac have...
The meteoric rise of the cannabis industry has seen the waning power of the prohibition era give way to multi-state dispensaries, sprawling cultivation operations, and hi-tech manufacturing facilities. However, one space remains off to a slow albeit deliberate start: cannabinoid-derived pharmaceuticals. With just four FDA-approved cannabinoid pharmaceuticals on the market...
Inozyme Pharma (NASDAQ:INZY) has been experiencing high levels of insider accumulation, with five net insiders acquiring shares over the last 90 days. Insider accumulation at the biotech company that develops therapies for rare mineralization disorders is bullish, with a Fintel score of 98.83, the seventh highest score when screened against 14,499 other stocks....